|
US6348469B1
(en)
|
1995-04-14 |
2002-02-19 |
Pharma Pass Llc |
Solid compositions containing glipizide and polyethylene oxide
|
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
|
US6048547A
(en)
*
|
1996-04-15 |
2000-04-11 |
Seth; Pawan |
Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
|
|
GB9609094D0
(en)
*
|
1996-05-01 |
1996-07-03 |
Univ Strathclyde |
Delivery device
|
|
EP0811374A1
(de)
*
|
1996-05-29 |
1997-12-10 |
Pfizer Inc. |
Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
|
|
ATE314054T1
(de)
*
|
1996-10-25 |
2006-01-15 |
Shire Lab Inc |
Osmotisches verabreichungssystem für lösliche dosen
|
|
US6361796B1
(en)
*
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
|
DE19729273C2
(de)
*
|
1997-07-09 |
2000-08-17 |
Aventis Res & Tech Gmbh & Co |
Thermoplastische Mischung auf 1,4-alpha-D-Polyglucanbasis, Verfahren zu deren Herstellung und Verwendung
|
|
BR9812553B1
(pt)
|
1997-09-25 |
2010-06-01 |
|
formulação medicamentosa em pélete de difusão controlada e em um sistema matriz.
|
|
DE19747261A1
(de)
*
|
1997-10-25 |
1999-04-29 |
Bayer Ag |
Osmotisches Arzneimittelfreisetzungssystem
|
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
|
US5916595A
(en)
*
|
1997-12-12 |
1999-06-29 |
Andrx Pharmaceutials, Inc. |
HMG co-reductase inhibitor
|
|
US6099859A
(en)
*
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
|
WO2000025757A1
(en)
*
|
1998-10-29 |
2000-05-11 |
Merck & Co., Inc. |
Sustained release delivery of highly water-soluble compounds
|
|
ATE433318T1
(de)
*
|
1999-02-10 |
2009-06-15 |
Pfizer Prod Inc |
Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
|
|
US6706283B1
(en)
*
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
|
JP2003504415A
(ja)
*
|
1999-07-20 |
2003-02-04 |
メルク エンド カムパニー インコーポレーテッド |
持続放出性薬物分散剤輸送装置
|
|
JP2003520759A
(ja)
*
|
1999-08-31 |
2003-07-08 |
アンドルックス ファーマスーティカルズ インコーポレーテッド |
単位核を有する徐放性錠剤
|
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
|
DK1242055T3
(da)
*
|
1999-12-23 |
2008-07-21 |
Pfizer Prod Inc |
Hydrogelstyret doseringsform til lægemidler
|
|
YU43702A
(sh)
|
1999-12-23 |
2004-11-25 |
Pfizer Products Inc. |
Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
|
|
WO2001047498A2
(en)
|
1999-12-23 |
2001-07-05 |
Pfizer Products Inc. |
Hydrogel-driven layered drug dosage form comprising sertraline
|
|
US6248359B1
(en)
|
2000-01-05 |
2001-06-19 |
Laboratorios Phoenix U.S.A., Inc. |
Multi-tablet oxybutynin system for treating incontinence
|
|
MXPA02007254A
(es)
|
2000-02-04 |
2002-12-09 |
Depomed Inc |
Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
|
|
US6270797B1
(en)
*
|
2000-05-18 |
2001-08-07 |
Usv Limited |
Sustained release pharmaceutical composition containing glipizide and method for producing same
|
|
US20030086972A1
(en)
*
|
2000-08-09 |
2003-05-08 |
Appel Leah E. |
Hydrogel-driven drug dosage form
|
|
AU2002220248A1
(en)
*
|
2000-11-06 |
2002-05-15 |
Andrx Pharmaceuticals, Inc. |
Once a day antihistamine and decongestant formulation
|
|
US20030175349A1
(en)
*
|
2001-01-30 |
2003-09-18 |
Council Of Scientific And Industrial Research |
Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
|
|
CA2441064A1
(en)
*
|
2001-03-16 |
2002-09-26 |
Andrx Corporation |
Controlled release sulfonylurea formulation
|
|
BR0211317A
(pt)
*
|
2001-07-04 |
2004-12-14 |
Sun Pharmaceutical Ind Ltd |
Sistema para a liberação controlada de uma droga por meio de retenção gástrica
|
|
US20030091634A1
(en)
*
|
2001-09-14 |
2003-05-15 |
Pawan Seth |
Delayed release tablet of venlafaxin
|
|
MXPA04002973A
(es)
*
|
2001-09-28 |
2005-06-20 |
Johnson & Johnson |
Formas de dosis de liberacion modificada.
|
|
AU2003202879A1
(en)
*
|
2002-01-04 |
2003-07-24 |
Ivax Research, Inc. |
Drug delivery system for sustained delivery of glipizide
|
|
BR0307332A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
|
TW200302748A
(en)
*
|
2002-02-01 |
2003-08-16 |
Pfizer Prod Inc |
Osmotic delivery system
|
|
KR100453288B1
(ko)
*
|
2002-03-12 |
2004-10-21 |
한국화학연구원 |
약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
|
|
CA2487786A1
(en)
*
|
2002-05-31 |
2003-12-11 |
Alza Corporation |
Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
|
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
|
US20040052844A1
(en)
*
|
2002-09-16 |
2004-03-18 |
Fang-Hsiung Hsiao |
Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
|
|
US8092831B2
(en)
*
|
2002-11-08 |
2012-01-10 |
Andrx Pharmaceuticals, Llc |
Antihistamine and decongestant system
|
|
US7988993B2
(en)
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
|
US8293799B2
(en)
*
|
2003-12-29 |
2012-10-23 |
Osmotica Keresleedelmo és Szolgáltató KFT |
Osmotic device containing a venlafaxine salt and a salt having an ion in common
|
|
US20040241252A1
(en)
*
|
2003-05-29 |
2004-12-02 |
Abney Christopher Charles |
Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
|
|
CN1819821B
(zh)
*
|
2003-08-08 |
2010-10-13 |
拜奥维尔实验室国际股份有限公司 |
盐酸安非他酮的改良释放片剂
|
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
|
US20050181050A1
(en)
*
|
2004-01-28 |
2005-08-18 |
Collegium Pharmaceutical, Inc. |
Dosage forms using drug-loaded ion exchange resins
|
|
US20050196448A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Hai Yong Huang |
Polymeric compositions and dosage forms comprising the same
|
|
US20050196446A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
|
US20050196447A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
|
DE102004023069A1
(de)
|
2004-05-11 |
2005-12-08 |
Bayer Healthcare Ag |
Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
|
|
KR100574554B1
(ko)
*
|
2004-05-28 |
2006-04-27 |
한미약품 주식회사 |
니아신의 경구투여용 서방성 조성물
|
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
|
US20070036843A1
(en)
*
|
2005-01-28 |
2007-02-15 |
Collegium Pharmaceutical, Inc. |
Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents
|
|
KR100678421B1
(ko)
*
|
2005-02-11 |
2007-02-02 |
주식회사 씨티씨바이오 |
염산 탐스로신 함유 방출조절 제제
|
|
US8673352B2
(en)
|
2005-04-15 |
2014-03-18 |
Mcneil-Ppc, Inc. |
Modified release dosage form
|
|
BRPI0612802A2
(pt)
*
|
2005-07-07 |
2010-11-30 |
Farnam Co Inc |
composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis
|
|
CN102716490A
(zh)
*
|
2005-09-01 |
2012-10-10 |
卫材R&D管理有限公司 |
药物组合物的崩解性的改善方法
|
|
US20080241240A1
(en)
*
|
2006-08-24 |
2008-10-02 |
Hanall Pharmaceutical Co., Ltd. |
Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
|
|
WO2008023869A1
(en)
*
|
2006-08-24 |
2008-02-28 |
Hanall Pharmaceutical Co., Ltd. |
Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
GB0702974D0
(en)
*
|
2007-02-15 |
2007-03-28 |
Jagotec Ag |
Method and apparatus for producing a tablet
|
|
EP2074993A1
(de)
|
2007-12-19 |
2009-07-01 |
Biovail Laboratories International S.r.l. |
Venlafaxin enthaltende Filmtabletten mit modifizierter Wirkstofffreisetzung
|
|
EP2299983A4
(de)
*
|
2008-07-24 |
2012-10-10 |
Handa Pharmaceuticals Llc |
Stabilisierte atypische antipsychotische formulierung
|
|
US20100285125A1
(en)
*
|
2009-05-07 |
2010-11-11 |
Padma Venkitachalam Devarajan |
Delivery system for poorly soluble drugs
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
EP3064064A1
(de)
*
|
2009-09-30 |
2016-09-07 |
Acura Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur abschreckung vor missbrauch
|
|
PL2826467T3
(pl)
|
2010-12-22 |
2018-01-31 |
Purdue Pharma Lp |
Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
|
|
PH12013501345A1
(en)
|
2010-12-23 |
2022-10-24 |
Purdue Pharma Lp |
Tamper resistant solid oral dosage forms
|
|
AU2012246490B2
(en)
|
2011-04-18 |
2016-08-04 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
AU2012310251B2
(en)
*
|
2011-09-16 |
2016-01-21 |
Purdue Pharma L.P. |
Tamper resistant immediate release formulations
|
|
CN104968333B
(zh)
|
2012-11-30 |
2018-07-10 |
阿库拉制药公司 |
活性药物成分的自调节释放
|
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
|
PE20151301A1
(es)
|
2013-02-05 |
2015-09-16 |
Purdue Pharma Lp |
Formulaciones farmaceuticas resistentes a la manipulacion indebida
|
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
|
CA2912219C
(en)
|
2013-05-14 |
2021-11-16 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
JP6510628B2
(ja)
|
2014-03-26 |
2019-05-15 |
サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド |
乱用防止即時放出性被覆リザーバ固体剤形
|
|
EP3187491A4
(de)
|
2014-08-28 |
2018-08-01 |
Eisai R&D Management Co., Ltd. |
Hochreines chinolinderivat und verfahren zur herstellung davon
|
|
US20180028662A1
(en)
|
2015-02-25 |
2018-02-01 |
Eisai R&D Management Co., Ltd. |
Method for Suppressing Bitterness of Quinoline Derivative
|
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
CA2988707C
(en)
|
2015-06-16 |
2023-10-10 |
Eisai R&D Management Co., Ltd. |
Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
|
|
CN108135894B
(zh)
|
2015-08-20 |
2021-02-19 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
WO2017040607A1
(en)
|
2015-08-31 |
2017-03-09 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
|
CN110072528B
(zh)
|
2017-02-08 |
2022-04-26 |
卫材R&D管理有限公司 |
治疗肿瘤的药物组合物
|
|
WO2018212202A1
(en)
|
2017-05-16 |
2018-11-22 |
Eisai R&D Management Co., Ltd. |
Treatment of hepatocellular carcinoma
|
|
EP4057989A1
(de)
*
|
2019-11-14 |
2022-09-21 |
Pfizer Inc. |
1-(((2s,3s,4s)-3-ethyl-4-fluor-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisochinolin-6-carboxamid kombinationen und orale dosierungsformen
|